Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
Reiji Yoshimura, Asuka Katsuki, Kiyokazu Atake, Hikaru Hori, Ryohei Igata, Yuki KonishiDepartment of Psychiatry, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan Objectives: The etiology of depression remains unknown. There is, however, a growing body o...
Guardado en:
Autores principales: | Yoshimura R, Katsuki A, Atake K, Hori H, Igata R, Konishi Y |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/dc8c03dddd934c0cb294c6b809f6200e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Effect Of Fluvoxamine On Sleep Architecture Of Depressed Patients With Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study
por: Hao Y, et al.
Publicado: (2019) -
Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites
por: Yoshimura R, et al.
Publicado: (2019) -
Post-marketing observational program of the effectiveness of fluvoxamine for the treatment of depression in patients with neurological disorders: the FRIENDS study
por: Yahno NN, et al.
Publicado: (2017) -
Plasma disturbance of phospholipid metabolism in major depressive disorder by integration of proteomics and metabolomics
por: Gui SW, et al.
Publicado: (2018) -
Evaluation of cognitive impairment in patients with major depressive disorder in remission
por: Mustafa Ali, et al.
Publicado: (2021)